Catherine Klapholz

Catherine Klapholz has a diverse work experience in the field of scientific research. Catherine is currently employed as a Senior Scientist at Adrestia Therapeutics since September 2022. Prior to this, they worked at Nanna Therapeutics from July 2018 to August 2022, where they held the role of Project leader / Senior Scientist. During their time at Nanna Therapeutics, they focused on cell-based assay development and screening cascade for compound profiling to enable drug discovery. Catherine also worked on the development of high-throughput phenotypic screening based on functional assays for mitochondrial function and biomass. Additionally, they conducted target identification and mechanism of action (MoA) studies.

Before joining Nanna Therapeutics, Catherine worked at the University of Cambridge as a Research Scientist and Lab Manager from January 2009 to June 2018. Catherine gained experience and expertise in managing laboratory operations, conducting research, and overseeing projects. Prior to that, they worked as a Research Assistant at Hôpital Necker-Enfants Malades from July 2007 to September 2008, and at Hôpital Saint-Louis from February 2006 to December 2006. Catherine's research work during these periods contributed to the advancement of knowledge in their field.

Catherine's early career includes a role as a Research Assistant at Institut Curie - Research Centre from February 2004 to September 2005. Throughout their career, they have consistently demonstrated their commitment to scientific research and has contributed to various projects and studies in different organizations.

Catherine Klapholz began their education in 2002 at the University of Nancy, where they pursued a Master's degree in Proteomics. Catherine completed this program in 2003. Following that, Catherine Klapholz attended the University of Strasbourg, where they undertook a Master 1st year in Biochemistry and Molecular Biology. The duration of their studies at this institution is unknown.